Clinical trials: IDIOPATHIC PARKINSON'S DISEASE
Idiopathic Parkinson's Disease
Rotigotine Versus Placebo, A Study To Evaluate The Efficacy In Advanced Stage Idiopathic Parkinson's Disease Patients
The primary objective of this study was to demonstrate that Rotigotine transdermal patch is efficacious in Chinese subjects with advanced-stage Idiopathic Parkinson's Disease as an adjuvant therapy.
- Trial name
- NCT01646255
- Testing
- Rotigotine, L-dopa
- Where
- 24 sites in China
- Volunteers
- 346 people
- Sponsor
- UCB Pharma
Parkinson Disease
Safety and Initial Effectiveness of Transcranial MR Guided Focused Ultrasound for the Treatment of Parkinson's Disease
Safety and Effectiveness in ExAblate Neuro treatment of medication-refractory tremor in subjects with idiopathic Parkinson's disease.
- Trial name
- TDPD (NCT04002596)
- Testing
- ExAblate Neuro Thalamotomy Treatment
- Where
- 2 sites in China, Japan
- Volunteers
- 26 people
- Sponsor
- InSightec
Parkinson Disease
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ITI-214 in Parkinson's Disease
This is a Phase I/II randomized, double-blind, placebo-controlled, multiple rising dose study in patients with stable idiopathic Parkinson's disease (PD) to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics…
- Trial name
- NCT03257046
- Testing
- ITI-214
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Advanced Stage Parkinson's Disease
An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advanced-Stage Parkinson's Disease
The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of the rotigotine patch in subjects with advanced-stage idiopathic Parkinson's disease
- Trial name
- NCT00501969
- Testing
- Rotigotine
- Where
- 53 sites in Australia, Austria and 15 more
- Volunteers
- 395 people
- Sponsor
- UCB Pharma
Parkinson Disease
Dose Escalation Study of Cu(II)ATSM in Parkinson's Disease
Multicenter, open-label dose-escalation study
- Trial name
- NCT03204929
- Testing
- Cu(II)ATSM
- Where
- 2 sites in Australia
- Volunteers
- 31 people
- Sponsor
- Collaborative Medicinal Development Pty Limited
Idiopathic Parkinson's Disease
Placebo-controlled Study in Patients With Parkinson's Disease to Evaluate the Effect of Rotigotine on Non-motor Symptoms
The primary objective of this study was to demonstrate that Rotigotine improves non-motor symptoms compared to Placebo in subjects with Parkinson's Disease.
- Trial name
- NCT01300819
- Testing
- Rotigotine
- Where
- 87 sites in Austria, Belgium and 10 more
- Volunteers
- 349 people
- Sponsor
- UCB Pharma
Idiopathic Parkinson's Disease
PF-06669571 In Subjects With Idiopathic Parkinson's Disease
This study is designed to assess safety, tolerability and pharmacokinetic data for multiple doses of PF-06669571 in subjects with idiopathic Parkinson's disease.
- Trial name
- NCT02565628
- Testing
- PF-06669571
- Where
- 9 sites in United States
- Volunteers
- 20 people
- Sponsor
- Pfizer
Parkinson Disease
Efficacy Study of Light Therapy as an Adjunctive Treatment for Parkinson's Disease
Light treatment was originally employed in Parkinson's disease (PD) to determine if it might be effective in treating co-existing symptoms of depression and insomnia.
- Trial name
- NCT02175472
- Testing
- Spectramax light therapy device, Control light device
- Where
- 3 sites in United States, Netherlands
- Volunteers
- 92 people
- Sponsor
- PhotoPharmics, Inc.
Advanced Idiopathic Parkinson's Disease
Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain
This trial is being conducted to compare the impact of Rotigotine and Placebo on Chronic Pain associated with Parkinson's Disease among patients with advanced stages of the disease.
- Trial name
- DOLORES (NCT01744496)
- Testing
- Rotigotine
- Where
- 16 sites in United States, Germany and 2 more
- Volunteers
- 68 people
- Sponsor
- UCB BIOSCIENCES GmbH
Idiopathic Parkinson's Disease
Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's Disease
The objective of this study is to compare the pharmacokinetics and pharmacodynamics of IPX054, carbidopa-levodopa immediate-release tablets, and carbidopa-levodopa controlled-release tablets in subjects with idiopathic…
- Trial name
- NCT00279825
- Testing
- IPX054 200 mg, IPX054 250 mg, CD-LD IR
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Impax Laboratories, LLC
Idiopathic Parkinson's Disease
Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
To evaluate the safety and efficacy of two dose ranges of safinamide (High Dose: 150 to 200 mg/day and Low Dose: 50 to 100 mg/day) orally, as compared to Placebo, as add-on therapy in patients with early idiopathic Parkinson's…
- Trial name
- NCT00643045
- Testing
- Safinamide
- Volunteers
- 269 people
- Sponsor
- Newron Pharmaceuticals SPA
Parkinson's Disease
Safety and Biomarker Study of PTC-589 in Participants With Parkinson's Disease
Open-label study with 30-day run-in phase and adaptive design component to include more participants if deemed appropriate by investigators.
- Trial name
- NCT02462603
- Testing
- PTC-589
- Where
- 5 sites in United States, Germany and 1 more
- Volunteers
- 44 people
- Sponsor
- Edison Pharmaceuticals Inc
Parkinson's Disease
A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0031 to Patients With Parkinson's Disease
This study is conducted to evaluate the safety and tolerability of the drug product sNN0031, containing Platelet Derived Growth Factor (PDGF), when administered directly into one of the fluid filled cavities in the brain using an…
- Trial name
- NCT00866502
- Testing
- sNN0031
- Where
- 2 sites in Sweden
- Volunteers
- 12 people
- Sponsor
- Newron Sweden AB
Idiopathic Parkinson's Disease
An Open-Label Extension Trial to Assess the Safety and Tolerability of Long Term Treatment of Rotigotine in Subjects With Idiopathic Parkinson's Disease
The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of rotigotine in subjects with idiopathic PD.
- Trial name
- NCT00505687
- Testing
- Rotigotine
- Where
- 26 sites in United States, Austria and 6 more
- Volunteers
- 186 people
- Sponsor
- UCB Pharma
Idiopathic Parkinson's Disease
Change in Gastrointestinal Complaints After Switch From Oral Parkinson's Disease Treatment to Neupro® Transdermal Patch
The study intends to collect data on gastrointestinal symptoms (swallowing disorders, heartburn, feeling of fullness, nausea, vomiting, abdominal pain, diarrhea) and on patient satisfaction under everyday practice conditions…
- Trial name
- NON-GI (NCT01159691)
- Where
- 21 sites in Germany
- Volunteers
- 76 people
- Sponsor
- UCB Pharma GmbH
Parkinson Disease (PD), Idiopathic Parkinson's Disease
Assessment of the Safety, Immunogenicity, and Pharmacodynamics of TRB-001 in Patients With Early Idiopathic Parkinson's Disease
This is a randomized, placebo-controlled, double-blind, dose-finding phase 1b study with the purpose to assess the safety, immunogenicity and pharmacodynamics of TRB-001 in early idiopathic Parkinson's Disease patients.
- Trial name
- NCT07840027
- Testing
- TRB-001
- Where
- Austria
- Volunteers
- 36 people
- Sponsor
- Tridem Bioscience FlexCo
Parkinson Disease, Movement Disorders
Long-Term Follow-up Safety After DDS Implantation With/Without CDNF Infusions
This study is a follow up to the HP-CD-CL-2002 clinical study. It evaluates the long-term safety in patients with Parkinson's disease after implantation of an investigational drug delivery system (DDS) with or without infusions…
- Conditions
- Parkinson Disease, Movement Disorders, Neuro-Degenerative Disease, Nervous System Diseases
- Trial name
- NCT04228653
- Testing
- Renishaw Drug Delivery System
- Where
- 3 sites in Finland, Sweden
- Volunteers
- 15 people
- Sponsor
- Renishaw
Parkinson's Disease
Trial of Extended Treatment With Liatermin (r-metHuGDNF) Administered by Continuous Intraputaminal (IPu)Infusion to Subjects With Idiopathic Parkinson's Disease Who Have Completed a Previous Trial of Liatermin
The purpose of this study is to determine long-term efficacy of continuous IPu liatermin infusion administered with concomitant standard anti-Parkinsonian therapy.
- Trial name
- NCT00111982
- Testing
- Liatermin
- Volunteers
- 34 people
- Sponsor
- Amgen
Idiopathic Parkinson's Disease
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
Parkinson's disease is a major neurodegenerative disorder in which there is a progressive loss of nigrostriatal dopaminergic neurons.
- Trial name
- MOTION (NCT00605683)
- Testing
- Safinamide (as add-on therapy)
- Where
- 125 sites in United States, Argentina and 18 more
- Volunteers
- 679 people
- Sponsor
- Newron Pharmaceuticals SPA
Tremor Associated With Tremor Dominant Parkinson's Disease
A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Thalamotomy for the Treatment of Medication-Refractory Tremor Dominant Idiopathic Parkinson's Disease
The objectives of this study are to collect the long-term safety and effectiveness data of performing thalamotomy for tremor dominant Parkinson's Disease (TDPD) using the Exablate Neuro system.
- Trial name
- NCT04991831
- Testing
- Unilateral thalamotomy
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 50 people
- Sponsor
- InSightec